Alumis (ALMS) Competitors $4.36 +0.06 (+1.40%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$4.36 0.00 (0.00%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALMS vs. IMCR, MESO, SRPT, APGE, VCEL, BHVN, AUPH, EWTX, CDTX, and PAHCShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Immunocore (IMCR), Mesoblast (MESO), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Edgewise Therapeutics (EWTX), Cidara Therapeutics (CDTX), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Immunocore Mesoblast Sarepta Therapeutics Apogee Therapeutics Vericel Biohaven Aurinia Pharmaceuticals Edgewise Therapeutics Cidara Therapeutics Phibro Animal Health Alumis (NASDAQ:ALMS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Which has more risk and volatility, ALMS or IMCR? Alumis has a beta of -1.38, suggesting that its stock price is 238% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Do analysts prefer ALMS or IMCR? Alumis presently has a consensus target price of $20.17, indicating a potential upside of 362.54%. Immunocore has a consensus target price of $56.89, indicating a potential upside of 55.56%. Given Alumis' stronger consensus rating and higher possible upside, research analysts clearly believe Alumis is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Do institutionals & insiders believe in ALMS or IMCR? 84.5% of Immunocore shares are held by institutional investors. 40.7% of Alumis shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ALMS or IMCR more profitable? Alumis has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -119.15% -92.50% Immunocore -5.70%-5.40%-1.93% Does the media favor ALMS or IMCR? In the previous week, Immunocore had 5 more articles in the media than Alumis. MarketBeat recorded 8 mentions for Immunocore and 3 mentions for Alumis. Alumis' average media sentiment score of 1.19 beat Immunocore's score of 0.81 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ALMS or IMCR? Immunocore has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AImmunocore$310.20M5.94-$51.09M-$0.40-91.43 SummaryAlumis and Immunocore tied by winning 7 of the 14 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$447.48M$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E RatioN/A21.6075.0626.20Price / SalesN/A297.80472.2591.86Price / CashN/A45.3337.0859.91Price / Book0.799.7112.246.28Net Income-$294.23M-$53.33M$3.29B$270.85M7 Day Performance-3.33%1.04%1.56%3.58%1 Month Performance-2.24%9.93%7.88%6.67%1 Year Performance-61.28%13.80%63.05%27.73% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis3.3578 of 5 stars$4.36+1.4%$20.17+362.5%-60.1%$447.48MN/A0.00N/APositive NewsIMCRImmunocore1.8692 of 5 stars$36.84+4.5%$56.89+54.4%+10.9%$1.85B$310.20M-91.72320MESOMesoblast1.5968 of 5 stars$14.37+6.3%$18.00+25.3%+148.7%$1.84B$17.20M0.0080SRPTSarepta Therapeutics4.4678 of 5 stars$18.77+1.7%$43.50+131.8%-86.1%$1.83B$1.90B-21.491,372Trending NewsAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.9298 of 5 stars$37.96+2.2%$97.29+156.3%-26.4%$1.75BN/A-9.1991News CoveragePositive NewsVCELVericel3.1089 of 5 stars$34.21+1.6%$60.40+76.6%-23.3%$1.73B$237.22M284.95300Positive NewsBHVNBiohaven3.3012 of 5 stars$15.92-1.0%$55.71+250.1%-60.4%$1.68BN/A-2.08239Trending NewsAUPHAurinia Pharmaceuticals2.9892 of 5 stars$12.56+0.2%$12.00-4.4%+95.7%$1.65B$235.13M29.20300Positive NewsEWTXEdgewise Therapeutics2.668 of 5 stars$15.64+7.0%$40.55+159.2%-12.9%$1.65BN/A-10.1160Positive NewsCDTXCidara Therapeutics3.3128 of 5 stars$63.42-2.3%$64.14+1.1%+458.3%$1.61B$1.27M-5.6990Positive NewsPAHCPhibro Animal Health4.5493 of 5 stars$39.39+0.8%$28.40-27.9%+101.4%$1.60B$1.30B33.382,475Trending NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies IMCR Alternatives MESO Alternatives SRPT Alternatives APGE Alternatives VCEL Alternatives BHVN Alternatives AUPH Alternatives EWTX Alternatives CDTX Alternatives PAHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
